NCT05824832 Buprenorphine, Clonidine, and Dexamethasone on Duration of Brachial Plexus Blocks for Upper Extremity Surgery
| NCT ID | NCT05824832 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Loyola University |
| Condition | Pain, Postoperative |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2023-02-28 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 120 participants in total. It began in 2023-02-28 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if there is a difference in morphine requirements in patients after upper extremity surgeries including shoulder arthroscopy. The main question it aims to answer is whether there is a difference between Interscalene brachial plexus blocks with the addition of buprenorphine, dexamethasone, and clonidine and the same block without the adjuvant.
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years old * Patients undergoing shoulder arthroscopy * Patients willing to participate and sign informed consent Exclusion Criteria: * Severe COPD/other contraindication to general anesthesia * Patient with a weight of less than 60 kg * Dementia, not alert or oriented to person, place, or time * Chronic pain patient with daily opioid use at home. * Patient with allergy to local anesthetics * Patient refusal * Total shoulder arthroplasty * Concomitant pain in different area from operative site. * Pregnancy * Patient with active infection on the injection sites for the blocks * Patients unable or willing to understand or comply with the study protocol
Contact & Investigator
Audrice Francois, MD
PRINCIPAL INVESTIGATOR
Loyola University Chicago
Frequently Asked Questions
Who can join the NCT05824832 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pain, Postoperative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05824832 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05824832 currently recruiting?
Yes, NCT05824832 is actively recruiting participants. Contact the research team at sfargo@luc.edu for enrollment information.
Where is the NCT05824832 trial being conducted?
This trial is being conducted at Maywood, United States.
Who is sponsoring the NCT05824832 clinical trial?
NCT05824832 is sponsored by Loyola University. The principal investigator is Audrice Francois, MD at Loyola University Chicago. The trial plans to enroll 120 participants.